313 related articles for article (PubMed ID: 37153619)
1. Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer.
Ge Y; Ye T; Fu S; Jiang X; Song H; Liu B; Wang G; Wang J
Front Immunol; 2023; 14():1114041. PubMed ID: 37153619
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
3. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
4.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
5. Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC.
Signorelli D; Ghidotti P; Proto C; Brambilla M; De Toma A; Ferrara R; Galli G; Ganzinelli M; Lo Russo G; Prelaj A; Occhipinti M; Viscardi G; Capizzuto V; Pontis F; Petraroia I; Ferretti AM; Colombo MP; Torri V; Sozzi G; Garassino MC; Jachetti E; Fortunato O
Front Immunol; 2022; 13():987639. PubMed ID: 36203609
[TBL] [Abstract][Full Text] [Related]
6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
7. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.
de Miguel-Perez D; Russo A; Gunasekaran M; Buemi F; Hester L; Fan X; Carter-Cooper BA; Lapidus RG; Peleg A; Arroyo-Hernández M; Cardona AF; Naing A; Hirsch FR; Mack PC; Kaushal S; Serrano MJ; Adamo V; Arrieta O; Rolfo C
Cancer; 2023 Feb; 129(4):521-530. PubMed ID: 36484171
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
Front Immunol; 2021; 12():799455. PubMed ID: 35069581
[TBL] [Abstract][Full Text] [Related]
9. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
Front Immunol; 2021; 12():638763. PubMed ID: 34305884
[TBL] [Abstract][Full Text] [Related]
10. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.
Zhang J; Zhou N; Lin A; Luo P; Chen X; Deng H; Kang S; Guo L; Zhu W; Zhang J
Cancer Immunol Immunother; 2021 Jan; 70(1):137-151. PubMed ID: 32653938
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
12. VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment.
Zhao Y; Guo S; Deng J; Shen J; Du F; Wu X; Chen Y; Li M; Chen M; Li X; Li W; Gu L; Sun Y; Wen Q; Li J; Xiao Z
Int J Biol Sci; 2022; 18(9):3845-3858. PubMed ID: 35813484
[TBL] [Abstract][Full Text] [Related]
13. Extracellular vesicle-based drug delivery in cancer immunotherapy.
Najafi S; Majidpoor J; Mortezaee K
Drug Deliv Transl Res; 2023 Nov; 13(11):2790-2806. PubMed ID: 37261603
[TBL] [Abstract][Full Text] [Related]
14. Roles of tissue-resident immune cells in immunotherapy of non-small cell lung cancer.
Tang R; Wang H; Tang M
Front Immunol; 2023; 14():1332814. PubMed ID: 38130725
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors.
Brocco D; Lanuti P; Pieragostino D; Cufaro MC; Simeone P; Bologna G; Di Marino P; De Tursi M; Grassadonia A; Irtelli L; De Lellis L; Veschi S; Florio R; Federici L; Marchisio M; Miscia S; Cama A; Tinari N; Del Boccio P
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546102
[TBL] [Abstract][Full Text] [Related]
16. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer.
de Miguel-Perez D; Russo A; Arrieta O; Ak M; Barron F; Gunasekaran M; Mamindla P; Lara-Mejia L; Peterson CB; Er ME; Peddagangireddy V; Buemi F; Cooper B; Manca P; Lapidus RG; Hsia RC; Cardona AF; Naing A; Kaushal S; Hirsch FR; Mack PC; Serrano MJ; Adamo V; Colen RR; Rolfo C
J Exp Clin Cancer Res; 2022 Jun; 41(1):186. PubMed ID: 35650597
[TBL] [Abstract][Full Text] [Related]
17. Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions.
Bhalla S; Doroshow DB; Hirsch FR
Cancer J; 2020; 26(6):507-516. PubMed ID: 33298722
[TBL] [Abstract][Full Text] [Related]
18. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
Peters S; Paz-Ares L; Herbst RS; Reck M
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858709
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
[TBL] [Abstract][Full Text] [Related]
20. Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
Li S; Zhang C; Pang G; Wang P
Front Immunol; 2020; 11():603157. PubMed ID: 33178229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
